Glaukos

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Glaukos reports robust Q4 earnings, sets ambitious growth plans for 2023

Glaukos delivered strong financial performance in Q4 2022 and outlined ambitious plans for 2023, focusing on innovation and market expansion. Despite staffing challenges and operating expense growth, the company remains optimistic about its growth prospects. Opportunities in advancing key products and addressing market dynamics position Glaukos for continued success.

Glaukos reports strong Q1 earnings, eyes international market opportunities

Glaukos delivered robust financial results in Q1 2023, showcasing growth in key franchises and advancing its pipeline. The company faces challenges in operational efficiency and market expansion but holds opportunities in international markets and innovative product offerings. Overall, Glaukos remains well-positioned for future growth and success.

Glaukos reports record Q2 sales, eyes international growth opportunities

Glaukos delivered strong Q2 results, with a focus on strategic investments for iDose launch and maintaining growth momentum. Challenges include reimbursement changes and healthcare trend normalization. Opportunities lie in international expansion and new product launches.

Glaukos reports robust Q3 sales, eyes early glaucoma intervention

Glaukos shows strong performance with sales growth and strategic developments.
Facing challenges in market share and FDA concerns but seizing growth opportunities.
Confidence in ongoing projects and commitment to advancing glaucoma therapies.
Strategic focus on innovation and market expansion in the glaucoma sector.

Glaukos achieves record sales, focuses on innovation and market growth

Glaukos delivered strong financial performance, with a focus on innovation and market leadership in the ophthalmic space.
The company's strategic strengths lie in its product portfolio, market access initiatives, and commitment to driving change in the standard of care.
Challenges include managing physician time allocation, balancing growth strategies, and ensuring successful product launches.
Opportunities for Glaukos include increased adoption of innovative products, pipeline advancements, and continued investment in driving future growth.

Glaukos reports record sales and raises guidance for 2024

Glaukos is on track for strong financial performance with record sales and increased guidance. The company faces challenges with iDose adoption and reimbursement timelines but sees opportunities for growth in various product lines.

Glaukos reports record Q2 sales, raises guidance amid innovation focus

Glaukos delivered strong financial performance in Q2 2024, with record net sales and raised full year guidance, driven by robust sales across key franchises.
The company's focus on innovation, balance sheet strengthening, and market expansion positions it well for future growth and competitive advantage.
While facing regulatory and operational challenges, Glaukos has opportunities to capitalize on market trends, product adoption, and international expansion.
Navigating these challenges and leveraging opportunities will be crucial for Glaukos to sustain growth momentum and enhance shareholder value.

Glaukos reports record Q3 sales, eyes growth through product launches

Glaukos delivered strong financial performance in Q3 2024, with record net sales and raised full year guidance. The company's focus on product innovation, market expansion, and reimbursement strategies positions it well for future growth. While challenges in financial restructuring and market access exist, opportunities in product launches and international expansion offer promising prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the iStent infinite® Trabecular Micro-Bypass System indicated for use in a standalone procedure to reduce elevated intraocular pressure (IOP) in patients with pri

Glaukos Announces FDA 510(k) Clearance of iStent infinite®

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2022. Key highlights include: Net sales of $72.7 million in Q2 2022. Glaucoma net sales of $56.1 million and Corneal Health net sales of $16.6 million in Q2 2022. Gross margin of approximately 75%

Glaukos Corporation Announces Second Quarter 2022 Financial Results

Does Glaukos (GKOS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Glaukos (GKOS) is a Great Momentum Stock to Buy

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Here's Why You Should Add Glaukos (GKOS) to Your Portfolio

Jazz Pharmaceuticals

Spectrum Pharma

JAZZ, GKOS and SPPI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13, 2022.

Best Momentum Stocks to Buy for July 13th

Here is how Glaukos (GKOS) and Alkermes (ALKS) have performed compared to their sector so far this year.

Has Glaukos (GKOS) Outpaced Other Medical Stocks This Year?

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2022 financial results after the market close on Wednesday, August 3, 2022. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on August 3, 2022. A link to t

Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3

Analog Devices

Livent Corp

Radius Global Infrastructure Inc

SiTime Corporation

Silicon Laboratories

These are the 6 most aggressive growth stocks to buy in July. They reflect huge potential growth in their sales and/or their earnings.

The 6 Most Aggressive Growth Stocks to Buy in July

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Piper Sandler Ophthalmology Symposium on Monday, May 23, 2022, at 2:00 p.m. ET. A live and archived webcast for this event will be available in the Investors section of the Glaukos websit

Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium

Glaukos' (GKOS) soft Q1 results fail to impress investors.

Glaukos (GKOS) Stock Falls 25.9% Despite Q1 Earnings Beat

Glaukos Corporation (NYSE:GKOS ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Tom Burns – Chairman & Chief Executive Officer Joe Gilliam – President & Chief Operating Officer Alex Thurman – Chief Financial Officer Chris Lewis – Vice President of Investor Relations & Corporate Affairs Conference Call Participants Andrew Brackmann – William Blair Chris Cooley – Stephens Charles Wilson – Wells Fargo Phillip Dantoin – BTIG Drew Stafford – Piper Sandler Thomas Stephan – Stifel Allen Gong – JPMorgan David Kuang – Oppenheimer Operator Good afternoon. My name is Julien and I will be your conference operator today.

Glaukos Corporation (GKOS) CEO Tom Burns on Q1 2022 Results - Earnings Call Transcript

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2022. Key highlights include: Net sales of $67.7 million in Q1 2022. Glaucoma net sales of $51.5 million and Corneal Health net sales of $16.1 million in Q1 2022. Gross margin of approximately 75%

Glaukos Corporation Announces First Quarter 2022 Financial Results

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 22–26, 2022 in Washington, D.C. In addition, Glaukos is sponsoring an education

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2021 Sustainability Report. The report highlights the company's continued commitment and progress on environmental, social and governance (ESG) initiatives. The Sustainability Report can be found on the company's website here.

Glaukos Announces the Release of its 2021 Sustainability Report

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2022 financial results after the market close on Wednesday, May 4, 2022. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on May 4, 2022. A link to the liv

Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has commenced a Phase 2 clinical program for its third-generation iLink™ therapy designed to treat keratoconus. Glaukos' iLink pharmaceutical platform consists of novel single-use drug formulations that are bio-activated by proprietary systems

Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy

Despite reporting a fourth-quarter loss, Glaukos' (GKOS) results reflect a noticeable rise in revenues.

Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates

Glaukos Corporation (GKOS) CEO Tom Burns on Q4 2021 Results - Earnings Call Transcript

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021. Key highlights include: Net sales of $73.2 million in Q4 2021. Glaucoma net sales of $57.1 million and Corneal Health net sales of $16.2 million in Q4 2021. Gross margin of

Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Glaukos (GKOS) Q4 Earnings Expected to Decline

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced several executive leadership changes to support the company's future growth and strategic plans. The following executive changes will become effective on April 1, 2022: Joseph Gilliam will assume the new role of President and Chief Operating Officer. M

Glaukos Announces Executive Leadership Changes

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2021 financial results after the market close on Tuesday, February 22, 2022. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on February

Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22

Ophthalmic medical company Glaukos Corporation (NYSE: GKOS) announced data from the Phase 2b trial of iDose TR, a sustained-release travoprost implant. The data showed sustained and substantial reductions in intraocular pressure (IOP) in a 36-month analysis.

Glaukos' iDose TR Shows Sustained Reduction In Ocular Pressure, Favorable Safety Profile

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its iDose® TR sustained-release travoprost implant continued to provide sustained substantial reductions in intraocular pressure (IOP) in a 36-month analysis of the 36-month Phase 2b clinical trial conducted under a U.S. Investigational New Drug (

News for Glaukos Stock (GKOS)